Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Suzuki, Kenshi, Dimopoulos, Meletios A., Takezako, Naoki, Okamoto, Shinichiro, Shinagawa, Atsushi, Matsumoto, Morio, Kosugi, Hiroshi, Yoon, Sung-Soo, Huang, Shang-Yi, Qin, Xiang, Qi, Ming, Iida, Shinsuke
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5928154/
https://ncbi.nlm.nih.gov/pubmed/29712896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0071-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars